Reversal of profound and "deep" residual rocuronium-induced neuromuscular blockade by sugammadex: a neurophysiological study
Minerva Anestesiologica, 05/04/2012
Pavoni V et al - Neurophysiological monitoring using myogenic motor evoked potentials (mMEPs) confirmed that sugammadex provided a complete recovery from profound and “deep” residual rocuronium–induced neuromuscular blockade.
In this prospective trial, 30 consenting patients undergoing propofol-remifentanil anesthesia for spine surgery were enrolled and divided into two groups: Group 1, reversal of profound NMB (sugammadex 16mg/Kg, 3minutes after rocuronium 1.2mg/Kg) and Group 2, reversal of “deep” residual NMB (sugammadex 4mg/Kg, 15minutes after rocuronium 0.6mg/Kg).
Myogenic MEPs registrations of upper and lower limbs and the diaphragm were performed, as well as TOF monitoring.
After injection of 4mg/Kg of sugammadex, the means of recovery time of the basal mMEPs amplitudes (diaphragm, and lower limbs and upper limbs) were 124±9.6, 143±163, 151±207sec, respectively whereas after 16mg/Kg of sugammadex the times were 109±13.8, 124±0.6, and 135±14.1sec.
Times to TOF ratio 0.9 were 114±75 and 186±105sec in Group 1 and 2, respectively.
No serious adverse effects related to sugammadex and to electrical stimulation were reported.
No reoccurrence of neuromuscular block was observed.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.